Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 12154028
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Angiogenesis in hematologic malignancies.

  2003cited by this paper
• Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6

  2002cited by this paper
• Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer

  2002cited by this paper
• Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma

  2002cited by this paper
• Combined modality radioimmunotherapy

  2002cited by this paper
• Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist

  2001cited by this paper
• Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.

  2001cited by this paper
• Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.

  2001cited by this paper
• Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth

  2001cited by this paper
• Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.

  2001cited by this paper
• Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts

  2001cited by this paper
• Antiangiogenic agents and their promising potential in combined therapy.

  2001cited by this paper
• Integrin activation controls metastasis in human breast cancer.

  2001cited by this paper
• Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia

  2001cited by this paper
• Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.

  2001cited by this paper
• Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature.

  2001cited by this paper
• Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.

  2001cited by this paper
• Neovascular Targeting with Cyclic RGD Peptide (cRGDf-ACHA) to Enhance Delivery of Radioimmunotherapy

  2000cited by this paper
• Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases

  2000cited by this paper
• Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

  2000cited by this paper
• Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.

  2000cited by this paper
• Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts.

  2000cited by this paper
• Detection of apoptosis in tissue sections

  2000cited by this paper
• Experimental radioimmunotherapy.

  2000cited by this paper
• NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity.

  2000cited by this paper
• Antitumor interaction of short-course endostatin and ionizing radiation.

  2000cited by this paper
• The Hemostatic System as a Regulator of Angiogenesis*

  2000cited by this paper
• Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas.

  2000cited by this paper
• Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.

  2000cited by this paper
• In vitro and in vivo effects of a cyclic peptide with affinity for the alpha(nu)beta3 integrin in human melanoma cells.

  2000cited by this paper
• In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.

  2000cited by this paper
• Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

  1999cited by this paper
• Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.

  1999cited by this paper
• Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.

  1999cited by this paper
• Combination Vascular Targeted and Tumor Targeted Radioimmunotherapy

  1999cited by this paper
• N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.

  1999cited by this paper
• Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.

  1999cited by this paper
• Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor‐2

  1999cited by this paper
• Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.

  1999cited by this paper
• Combined Modality Radioimmunotherapy with Taxol and 90Y-LYM-1 for Raji Lymphoma Xenografts

  1998cited by this paper
• Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer.

  1998cited by this paper
• Perspectives of combined radioimmunotherapy and anti‐EGFR antibody therapy for the treatment of residual head and neck cancer

  1998cited by this paper
• Adhesion of Activated Platelets to Endothelial Cells: Evidence for a GPIIbIIIa-dependent Bridging Mechanism and Novel Roles for Endothelial Intercellular Adhesion Molecule 1 (ICAM-1), αvβ3 Integrin, and GPIbα

  1998cited by this paper
• X-ray-induced P-selectin localization to the lumen of tumor blood vessels.

  1998cited by this paper
• Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin.

  1998cited by this paper
• Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.

  1998cited by this paper
• Combined effects of angiostatin and ionizing radiation in antitumour therapy

  1998cited by this paper
• Bcl2 is the guardian of microtubule integrity.

  1997cited by this paper
• p53‐independent response of a human breast carcinoma xenograft to radioimmunotherapy

  1997cited by this paper
• Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.

  1997cited by this paper
• Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas.

  1997cited by this paper
• Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).

  1997cited by this paper
• Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma

  1997cited by this paper
• Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies.

  1996cited by this paper
• Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis.

  1996cited by this paper
• An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice.

  1995cited by this paper
• Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.

  1995cited by this paper
• Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells.

  1995cited by this paper
• Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.

  1995cited by this paper
• bcl-2 suppresses expression of p21WAF1/CIP1 in breast epithelial cells.

  1995cited by this paper
• Requirement of vascular integrin alpha v beta 3 for angiogenesis.

  1994cited by this paper
• bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.

  1994cited by this paper
• Apoptosis. Its significance in cancer and cancer Therapy

  1994cited by this paper
• Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.

  1994cited by this paper
• Membrane topology of the L6 antigen and identification of the protein epitope recognized by the L6 monoclonal antibody.

  1994cited by this paper
• Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.

  1992cited by this paper
• Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

  1992cited by this paper
• Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site.

  1992cited by this paper
• Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.

  1992cited by this paper
• Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.

  1991cited by this paper
• Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines.

  1990cited by this paper
• Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure.

  1988cited by this paper
• Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells.

  1987cited by this paper
• Vascular endothelium as the vulnerable element in tumours.

  1984cited by this paper
• Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

  1984cited by this paper

• Targeting Matrix Stiffness and Mechanotransduction in Breast Cancer: Implications for Emerging Therapies

  2026cites this paper
• Interaction of integrin αvβ3 and fibronectin under fluid shear forces: implications for tumor cell adhesion and migration

  2025cites this paper
• The synergistic potential of mechanotherapy and sonopermeation to enhance cancer treatment effectiveness

  2025cites this paper
• A novel class of inhibitors that disrupts the stability of integrin heterodimers identified by CRISPR-tiling-instructed genetic screens

  2024cites this paper
• Cilengitide sensitivity is predicted by overall integrin expression in breast cancer

  2024cites this paper
• Click processes orthogonal to CuAAC and SuFEx forge selectively modifiable fluorescent linkers

  2023cites this paper
• Heparan sulfate dependent binding of plasmatic von Willebrand factor to blood circulating melanoma cells attenuates metastasis.

  2022cites this paper
• Pathophysiological roles of integrins in gliomas from the perspective of glioma stem cells

  2022cites this paper
• An integrated computational pipeline for designing high-affinity nanobodies with expanded genetic codes

  2021cites this paper
• Non-Cationic RGD-Containing Protein Nanocarrier for Tumor-Targeted siRNA Delivery

  2021cites this paper
• Integrins as attractive targets for cancer therapeutics

  2021cites this paper
• Elucidating Solution Structures of Cyclic Peptides Using Molecular Dynamics Simulations.

  2021cites this paper
• Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma.

  2020cites this paper
• ITGAV targeting as a therapeutic approach for treatment of metastatic breast cancer.

  2020cites this paper
• Bacterial-Like Nonribosomal Peptide Synthetases Produce Cyclopeptides in the Zygomycetous Fungus Mortierella alpina

  2020cites this paper
• The secreted protein DEL-1 activates a β3 integrin–FAK–ERK1/2–RUNX2 pathway and promotes osteogenic differentiation and bone regeneration

  2020cites this paper
• EDIL3 promotes epithelial–mesenchymal transition and paclitaxel resistance through its interaction with integrin αVβ3 in cancer cells

  2020cites this paper
• Connections between the cell cycle, cell adhesion and the cytoskeleton

  2019cites this paper
• Antitumor activity of integrin αVβ3 antibody conjugated-cationic microbubbles in liver cancer

  2019cites this paper
• Expression of CTGF/CCN2 in response to LPA is stimulated by fibrotic extracellular matrix via the integrin/FAK axis.

  2018cites this paper
• Disassembling a cancer puzzle: Cell junctions and plasma membrane as targets for anticancer therapy

  2018cites this paper
• Les cellules initiatrices de tumeurs à l'origine de l'hétérogénéité d'expression de l'intégrine α5β1 dans les glioblastomes

  2018cites this paper
• An αv-RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities.

  2018cites this paper
• Mechanisms of invasion and motility of high-grade gliomas in the brain

  2018cites this paper
• Proapoptotic Cyclic Peptide BC71 Targets Cell-Surface GRP78 and Functions as an Anticancer Therapeutic in Mice

  2018cites this paper
• Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, suppresses tumor growth in mice via impeding both angiogenesis and vascular permeability

  2018cites this paper
• Drug conjugates—an emerging approach to treat breast cancer

  2018cites this paper
• Tetraiodothyroacetic acid-conjugated polyethylenimine for integrin receptor mediated delivery of the plasmid encoding IL-12 gene.

  2017cites this paper
• Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.

  2017cites this paper
• Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients

  2017cites this paper
• Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model.

  2017cites this paper
• Adhesion molecules and the extracellular matrix as drug targets for glioma

  2016cites this paper
• In vitro models of cancer stem cells and clinical applications

  2016cites this paper
• Anion–π interactions in complexes of proteins and halogen-containing amino acids

  2016cites this paper
• CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation

  2016cites this paper
• Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model

  2016cites this paper
• Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3

  2016cites this paper
• Advancing theranostics with tumor-targeting peptides for precision otolaryngology

  2016influential citation
• In situ validation of VEGFR-2 and αvß3 integrin as targets for breast lesion characterization

  2016cites this paper
• Insight to the binding mode of triazole RGD-peptidomimetics to integrin-rich cancer cells by NMR and molecular modeling.

  2016cites this paper
• Targeting metastasis

  2016cites this paper
• Antiangiogenic mechanisms and factors in breast cancer treatment

  2016cites this paper
• Arg-Gly-Asp-D-Phe-Lys peptide-modified PEGylated dendrimer-entrapped gold nanoparticles for targeted computed tomography imaging of breast carcinoma.

  2015cites this paper
• Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin β3 and TGF-β receptor type II.

  2015cites this paper
• RNA-Binding Protein Musashi1 Is a Central Regulator of Adhesion Pathways in Glioblastoma

  2015cites this paper
• Identification of putative drug targets for human sperm-egg interaction defect using protein network approach

  2015cites this paper
• Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins.

  2015cites this paper
• Virtual Screening Using Combinatorial Cyclic Peptide Libraries Reveals Protein Interfaces Readily Targetable by Cyclic Peptides

  2015cites this paper
• Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy

  2015cites this paper
• Anti-angiogenic alternatives to VEGF blockade

  2015cites this paper
• Chemo and Radioresistance in Brain-Related Tumors

  2014influential citation
• The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines

  2014cites this paper
• Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancer

  2014cites this paper
• Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy

  2014cites this paper
• Multimodal Molecular Imaging of Integrin αvβ3 for In Vivo Detection of Pancreatic Cancer

  2014cites this paper
• Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma

  2014cites this paper
• Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.

  2014cites this paper
• Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns

  2014cites this paper
• Bimodal anti‐glioma mechanisms of cilengitide demonstrated by novel invasive glioma models

  2013cites this paper
• Combination therapy of cilengitide with belotecan against experimental glioblastoma

  2013cites this paper
• In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines

  2013cites this paper
• Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway

  2013cites this paper
• Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme

  2013cites this paper
• The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus

  2013cites this paper
• Effects of N-acetyl-L-cysteine and Nitric Oxide-releasing Nonsteroidal Anti- Inflammatory Drugs on Breast Cancer and Melanoma Cell Adhesion

  2013cites this paper
• Gene expression profiling of the anti-glioma effect of Cilengitide

  2013cites this paper
• Monitoring glioma growth and tumor necrosis with the U-SPECT-II/CT scanner by targeting integrin αvβ3.

  2013cites this paper
• Etude des mécanismes d'action de nouvelles molécules utilisées seules ou en association avec les radiations ionisantes dans les cancers pédiatriques

  2013cites this paper
• Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression

  2013cites this paper
• Radioimmunotherapy for high-grade glioma.

  2013cites this paper
• Halogen bonding in complexes of proteins and non-natural amino acids

  2013cites this paper
• The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model

  2013cites this paper
• The a V b 3 / a V b 5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model

  2013cites this paper
• 64Cu-NODAGA-c(RGDyK) Is a Promising New Angiogenesis PET Tracer: Correlation between Tumor Uptake and Integrin α V β 3 Expression in Human Neuroendocrine Tumor Xenografts

  2012cites this paper
• ESTUDO DA CONTRIBUIÇÃO DAS INTEGRINAS NA MOTILIDADE DE CÉLULAS DE GLIOBLASTOMA

  2012cites this paper
• Cilengitide treatment for malignant glioma: current status and future direction.

  2012cites this paper
• The tumor stroma as mediator of drug resistance--a potential target to improve cancer therapy?

  2012cites this paper
• Chemoradiotherapy of human tumors: novel approaches from nanomedicine.

  2012cites this paper
• Peripheral functionalization of dendrimers regulates internalization and intracellular trafficking in living cells.

  2012cites this paper
• Radiolabelled RGD peptides for imaging and therapy

  2012cites this paper
• A phase I study of continuous infusion cilengitide in patients with solid tumors

  2012cites this paper
• The 70 th Annual Meeting Special Topics — Part II : Multidisciplinary Treatment for High Grade Gliomas Cilengitide Treatment for Malignant Glioma : Current Status and Future Direction

  2012cites this paper
• ¹²⁵I-radiolabeled morpholine-containing arginine-glycine-aspartate (RGD) ligand of αvβ₃ integrin as a molecular imaging probe for angiogenesis.

  2012cites this paper
• Integrin control of tumor invasion.

  2012cites this paper
• Tumor cell migration in complex microenvironments

  2012cites this paper
• SwissSidechain: a molecular and structural database of non-natural sidechains

  2012cites this paper
• Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.

  2011cites this paper
• Interventions that induce modifications in the tumor microenvironment.

  2011cites this paper
• Targeting integrins in hepatocellular carcinoma

  2011cites this paper
• Study into the role of lactadherin as a tumour associated antigen and angiogenesis factor : investigating HuMc3 (Angiolix®) as a therapeutic antibody for cancer

  2011cites this paper
• Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets

  2011cites this paper
• [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].

  2011cites this paper
• Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.

  2011cites this paper
• Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing I-labeled 125 monoclonal antibodies

  2011cites this paper
• Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies.

  2011cites this paper
• Roles of Integrins in the Development and Progression of Squamous Cell Carcinomas

  2011cites this paper
• Molecular Targets for Radiation Oncology in Prostate Cancer

  2011cites this paper
• Integrin Targeted Therapeutics

  2011cites this paper
• Cilengitide induces autophagy-mediated cell death in glioma cells.

  2011cites this paper
• CLT1 targets angiogenic endothelium through CLIC1 and fibronectin

  2011cites this paper